SEC Filing Analysis: NEUROCRINE BIOSCIENCES INC (NBIX)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director conducted a routine, pre-planned 'exercise-and-sell' transaction totaling approximately $946,000, representing a negligible fraction of the company's market capitalization.
• Market Impact: The transaction's low value and pre-scheduled nature under a 10b5-1 plan suggest a neutral market impact.

Company Information

Field	Value
Company	NEUROCRINE BIOSCIENCES INC
Ticker Symbol	NBIX
CIK	0000914475
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	Norwalk Leslie V
CIK	0001533568
Title/Position	null
Relationship	Director

Transaction Details

This filing reports multiple transactions, primarily an option exercise followed by sales. The most significant sale is detailed below.

Field	Value
Form Type	4
Transaction Date	2025-12-15
Transaction Code	S (Sale)
Security Type	Common Stock
Shares Involved	5,000
Price Per Share	$152.2287
Total Value	$761,143.50
Shares Owned After	7,429
Ownership Type	Direct

Financial Impact Assessment

Analysis is based on the aggregate sales of 6,190 shares for a total of ~$945,702.

Transaction Materiality

Metric	Value
Total Transaction Value	$945,702
% of Market Cap	0.0065%
Total Shares Transacted	6,190
% of Shares Outstanding	0.0062%
Post-Transaction Ownership	6,239 shares (0.0063% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a large-cap company with a market capitalization of $14.44 billion, a sale of less than $1 million is financially immaterial.
• Ownership Concentration: The director's post-transaction holding of 6,239 shares represents a very small fraction of the 99.18 million shares outstanding, indicating low ownership concentration.
• Transaction Significance: The sale represents a negligible 0.0065% of the company's market cap. Such transactions are routine and do not typically influence market sentiment.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sale was executed under a pre-disclosed Rule 10b5-1 trading plan, which severs the link between the transaction and any potential non-public information the insider may possess at the time of the sale. The value is also too small to be material.

Volume & Sentiment

• Expected Volume Impact: Minimal. The transaction size is insignificant compared to the stock's typical daily trading volume.
• Sentiment Indicator: Neutral. Pre-planned sales by non-executive directors are common for personal financial management and are not typically viewed as a bearish signal.

Additional Context

Special Circumstances

• The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the insider on September 12, 2025. This indicates the sales were pre-scheduled and not based on immediate market conditions or a change in outlook.